title: Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.
abstract: OBJECTIVE
  The outcome of portal vein thrombosis in relation to associated prothrombotic states has not been evaluated. We assessed current outcome and predictors of bleeding and thrombotic events in a cohort of 136 adults with nonmalignant, noncirrhotic portal vein thrombosis, of whom 84 received anticoagulant therapy.
  
  
  METHODS
  Multivariate Cox model analysis for event-free survival and analysis taking into account multiple events were used.
  
  
  RESULTS
  Median follow-up was 46 months. The incidence rate of gastrointestinal bleeding was 12.5 (95% confidence interval [CI], 10-15) per 100 patient-years. Large varices were an independent predictor for bleeding. Anticoagulant therapy did not increase the risk or the severity of bleeding. The incidence rate of thrombotic events was 5.5 (95% CI, 3.8-7.2) per 100 patient-years. Underlying prothrombotic state and absence of anticoagulant therapy were independent predictors for thrombosis. In patients with underlying prothrombotic state, the incidence rates of splanchnic venous infarction were 0.82 and 5.2 per 100 patient-years in periods with and without anticoagulant therapy, respectively (P = 0.01). Two nonanticoagulated patients died of bleeding and thrombosis, respectively.
  
  
  CONCLUSIONS
  In patients with portal vein thrombosis, the risk of thrombosis is currently as clinically significant as the risk of bleeding. The benefit-risk ratio favors anticoagulant therapy.
authors.affiliation: Service d'hépatologie et INSERM Unité 481, Fédération médico-chirurgicale d'hépatogastroentérologie, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Condat
authors.forename: F
authors.initials: F
authors.lastname: Pessione
authors.forename: S
authors.initials: S
authors.lastname: Hillaire
authors.forename: M H
authors.initials: MH
authors.lastname: Denninger
authors.forename: M C
authors.initials: MC
authors.lastname: Guillin
authors.forename: M
authors.initials: M
authors.lastname: Poliquin
authors.forename: A
authors.initials: A
authors.lastname: Hadengue
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: D
authors.initials: D
authors.lastname: Valla
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011169:Portal Vein; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000925:Anticoagulants